Proteasome inhibitors and cardiac cell growth

Cardiovascular Research

Volumn 85, Issue 2, 2010, Pages 321-329

  Hedhli, Nadia ^a   Depre, Christophe ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Cell growth; Hypertrophy; Proteasome

Indexed keywords

ATROGIN 1; BORTEZOMIB; EPOXOMICIN; MUSCLE RING FINGER 1 PROTEIN; PROTEASOME; UBIQUITIN PROTEIN LIGASE E3;

CELL GROWTH; DRUG MECHANISM; ENZYME INHIBITION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW;

ANIMALS; CARDIOMEGALY; CELL PROLIFERATION; HUMANS; MYOCYTES, CARDIAC; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BIOSYNTHESIS; PROTEINS; UBIQUITIN; VENTRICULAR REMODELING;

EID: 72949098600     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp226     Document Type: Review

References (98)

1. Etlinger JD, Goldberg AL. A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. Proc Natl Acad Sci USA 1977;74:54-58.
2. Ciechanover A, Hod Y, Hershko A. A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem Biophys Res Commun 1978;81:1100-1105.
3. Hershko A, Heller H, Elias S, Ciechanover A. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J Biol Chem 1983;258:8206-8214.
4. Meiners S, Ludwig A, Stangl V, Stangl K. Proteasome inhibitors: poisons and remedies. Med Res Rev 2008;28:309-327.
5. Powell SR. The ubiquitin-proteasome system in cardiac physiology and pathology. Am J Physiol Heart Circ Physiol 2006;291:H1-H19.
6. Hough R, Pratt G, Rechsteiner M. Purification of two high molecular weight proteases from rabbit reticulocyte lysate. J Biol Chem 1987;262:8303-8313.
7. Drews O, Zong C, Ping P. Exploring proteasome complexes by proteomic approaches. Proteomics 2007;7:1047-1058.
8. Tanaka K, Yoshimura T, Kumatori A, Ichihara A, Ikai A, Nishigai M et al. Protea-somes (multi-protease complexes) as 20S ring-shaped particles in a variety of eukaryotic cells. J Biol Chem 1988;263:16209-16217.
9. Rechsteiner M, Hill C. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol 2005;15:27-33.
10. Ahn K, Erlander M, Leturcq D, Peterson PA, Fruh K, Yang Y. In vivo characterization of the proteasome regulator PA28. J Biol Chem 1996;271:18237-18242.
11. Rechsteiner M, Realini C, Ustrell V. The proteasome activator 11S REG (PA28) and class I antigen presentation. Biochem J 2000;345(Pt. 1):1-15.
12. Layfield R, Lowe J, Bedford L. The ubiquitin-proteasome system and neurodegen-erative disorders. Essays Biochem 2005;41:157-171.
13. Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH et al. Global changes to the ubiquitin system in Huntington's disease. Nature 2007;448: 704-708.
14. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hema-tologic malignancies. J Clin Oncol 2002;20:4420-4427.
15. Zavrski I, Jakob C, Kaiser M, Fleissner C, Heider U, Sezer O. Molecular and clinical aspects of proteasome inhibition in the treatment of cancer. Recent Results Cancer Res 2007;176:165-176.
16. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-2511.
17. Chuang SM, Madura K. Saccharomyces cerevisiae Ub-conjugating enzyme Ubc4 binds the proteasome in the presence of translationally damaged proteins. Genetics 2005;171:1477-1484.
18. Wang X, Robbins J. Heart failure and protein quality control. Circ Res 2006;99: 1315-1328.
19. Tsukamoto O, Minamino T, Okada K, Shintani Y, Takashima S, Kato H et al. Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice. Biochem Biophys Res Com 2006;340: 1125-1133.
20. Bulteau A-L, Lundberg KC, Humphries KM, Sadek HA, Szweda PA, Friguet B et al. Oxidative modification and inactivation of the proteasome during coronary occlu-sion/reperfusion. J Biol Chem 2001;276:30057-30063.
21. Sin N, Kim KB, Elofsson M, Meng L, Auth H, Kwok BH et al. Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding protea-some biology. Bioorg Med Chem Lett 1999;9:2283-2288.
22. Craiu A, Gaczynska M, Akopian T, Gramm CF, Fenteany G, Goldberg AL et al. Lactacystin and clasto-lactacystin b-lactone modify multiple proteasome b-subunits and inhibit intracellular protein degradation and major histocompat-ibility complex class I antigen presentation. J Biol Chem 1997;272:13437-13445.
23. Depre C, Wang Q, Yan L, Hedhli N, Peter P, Chen L et al. Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 2006;114:1821-1828.
24. Hedhli N, Wang L, Wang Q, Rashed E, Tian Y, Sui X et al. Proteasome activation during cardiac hypertrophy by the chaperone H11 Kinase/Hsp22. Cardiovasc Res 2008;77:497-505.
25. Hedhli N, Lizano P, Hong C, Fritzky LF, Dhar SK, Liu H et al. Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload. Am J Physiol Heart Circ Physiol 2008;295:H1385-H1393.
26. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 2003;100:9946-9951.
27. Oyadomari S, Yun C, Fisher EA, Kreglinger N, Kreibich G, Oyadomari M et al. Cotranslocational degradation protects the stressed endoplasmic reticulum from protein overload. Cell 2006;126:727-739.
28. Marciniak S, Ron D. Endoplasmic reticulum stress signaling in disease. Physiol Rev 2006;86:1133-1149.
29. Nawrocki S, Carew J, Pino M, Highshaw R, Dunner K, Huang P et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apop-tosis. Cancer Res 2005;65:11658-11666.
30. Obeng E, Carlson L, Gutman D, Harrington W, Lee K, Boise L. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-4916.
31. Appelman YE, Doevendans PA. Proteasome inhibition and stress compromise the heart in chemotherapy. Cardiovasc Res 2008;79:547-548.
32. Fu H, Minamino T, Tsukamoto O, Sawada T, Asai M, Kato H et al. Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition. Cardiovasc Res 2008;79:600-610.
33. Voortman J, Giaccone G. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer 2006;6:129.
34. Hacihanefioglu A, Tarkun P, Gonullu E. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol 2008;88:219-222.
35. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231-2247.
36. Itoh M, Takaoka M, Shibata A, Ohkita M, Matsumura Y. Preventive effect of lacta-cystin, a selective proteasome inhibitor, on ischemic acute renal failure in rats. J Pharmacol Exp Ther 2001;298:501-507.
37. Pye J, Ardeshirpour F, McCain A, Bellinger DA, Merricks E, Adams J et al. Protea-some inhibition ablates activation of NF-kB in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol 2003;284:H919-H926.
38. Zhang L, Zhang ZG, Liu X, Hozeska A, Stagliano N, Riordan W et al. Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasmino-gen activator. Thromb Haemost 2006;95:166-173.
39. Meiners S, Hocher B, Weller A, Laule M, Stangl V, Guenther C et al. Downregula-tion of matrix metalloproteinases and collagens and suppression of cardiac fibro-sis by inhibition of the proteasome. Hypertension 2004;44:471-477.
40. Roodman GD. Bone building with bortezomib. J Clin Invest 2008;118:462-464.
41. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 1999;96:10403-10408.
42. Kisselev AF, Callard A, Goldberg AL. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 2006;281:8582-8590.
43. Gomes AV, Young GW, Wang Y, Zong C, Eghbali M, Drews O et al. Contrasting proteome biology and functional heterogeneity of the 20S proteasome complexes in mammalian tissues. Mol Cell Proteomics 2009;8:302-315.
44. Eble DM, Spragia ML, Ferguson AG, Samarel AM. Sarcomeric myosin heavy chain is degraded by the proteasome. Cell Tissue Res 1999;296:541-548.
45. Taylor RG, Tassy C, Briand M, Robert N, Briand Y, Ouali A. Proteolytic activity of proteasome on myofibrillar structures. Mol Biol Rep 1995;21:71-73.
46. Field ML, Clark JF. Inappropriate ubiquitin conjugation: a proposed mechanism contributing to heart failure. Cardiovasc Res 1997;33:8-12.
47. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294:1704-1708.
48. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 2001;98:14440-14445.
49. Gaussin V, Tomlinson JE, Depre C, Engelhardt S, Antos CL, Takagi G et al. Common genomic response in different mouse models of b adrenergic-induced cardiomyopathy. Circulation 2003;108:2926-2933.
50. Li HH, Kedar V, Zhang C, McDonough H, Arya R, Wang DZ et al. Atrogin-1/ muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest 2004;114:1058-1071.
51. Kedar V, McDonough H, Arya R, Li H-H, Rockman HA, Patterson C. Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac tropo-nin I. Proc Natl Acad Sci USA 2004;101:18135-18140.
52. Li C, Browder W, Kao RL. Early activation of transcription factor NF-kB during ischemia in perfused rat heart. Am J Physiol 1999;276:H543-H552.
53. Scheidereit C. IkB kinase complexes: gateways to NF-kB activation and transcription. Oncogene 2006;25:6685-6705.
54. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008;58: 88-111.
55. Stansfield WE, Moss NC, Willis MS, Tang R, Selzman CH. Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myo-cardial ischemia-reperfusion injury. Ann Thorac Surg 2007;84:120-125.
56. Tomita H, Nazmy M, Kajimoto K, Yehia G, Molina CA, Sadoshima J. Inducible cAMP early repressor (ICER) is a negative-feedback regulator of cardiac hypertrophy and an important mediator of cardiac myocyte apoptosis in response to b-adrenergic receptor stimulation. Circ Res 2003;93:12-22.
57. Muller FU, Lewin G, Baba HA, Boknik P, Fabritz L, Kirchhefer U et al. Heart-directed expression of a human cardiac isoform of cAMP-response element modulator in transgenic mice. J Biol Chem 2005;280:6906-6914.
58. Folco E, Koren G. Degradation of the inducible cAMP early repressor (ICER) by the ubiquitin-proteasome pathway. Biochem J 1997;328:37-43.
59. Pati D, Meistrich ML, Plon SE. Human Cdc34 and Rad6B ubiquitin- conjugating enzymes target repressors of cyclic AMP-induced transcription for proteolysis. Mol Cell Biol 1999;19:5001-5013.
60. Spence J, Gali RR, Dittmar G, Sherman F, Karin M, Finley D. Cell cycle-regulated modification of the ribosome by a variant multiubiquitin chain. Cell 2000;102: 67-76.
61. Stavreva DA, Kawasaki M, Dundr M, Koberna K, Muller WG, Tsujimura-Takahashi T et al. Potential roles for ubiquitin and the proteasome during ribosome biogenesis. Mol Cell Biol 2006;26:5131-5145.
62. Schubert U, Anton L, Gibbs J, Norbury C, Yewdell J, Bennink J. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000; 404:770-774.
63. Hotokezaka Y, Tobben U, Hotokezaka H, Van Leyen K, Beatrix B, Smith DH et al. Interaction of the eukaryotic elongation factor 1A with newly synthesized poly-peptides. J Biol Chem 2002;277:18545-18551.
64. Chuang SM, Chen L, Lambertson D, Anand M, Kinzy TG, Madura K. Proteasome-mediated degradation of cotranslationally damaged proteins involves translation elongation factor 1A. Mol Cell Biol 2005;25:403-413.
65. Cardin S, Pelletier P, Libby E, Le Bouter S, Xiao L, Kaab S et al. Marked differences between atrial and ventricular gene-expression remodeling in dogs with experimental heart failure. J Mol Cell Cardiol 2008;45:821-831.
66. Hein S, Arnon E, Kostin S, Schonburg M, Elsasser A, Polyakova V et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003; 107:984-991.
67. Weekes J, Morrison K, Mullen A, Wait R, Barton P, Dunn M. Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics 2003;3:208-216.
68. Powell SR, Samuel SM, Wang P, Divald A, Thirunavukkarasu M, Koneru S et al. Upregulation of myocardial 11S-activated proteasome in experimental hypergly-cemia. J Mol Cell Cardiol 2008;44:618-621.
69. Liu J, Zheng H, Tang M, Ryu YC, Wang X. A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome. Am J Physiol Heart Circ Physiol 2008; 295:H2541-H2550.
70. Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003; 107:1664-1670.
71. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004;109:3050-3055.
72. Meiners S, Dreger H, Fechner M, Bieler S, Rother W, Gunther C et al. Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension 2008;51:302-308.
73. Fang CX, Dong F, Thomas DP, Ma H, He L, Ren J. Hypertrophic cardiomyopathy in high-fat diet-induced obesity: role of suppression of forkhead transcription factor and atrophy gene transcription. Am J Physiol Heart Circ Physiol 2008;295: H1206-H1215.
74. Stansfield WE, Tang R-H, Moss NC, Baldwin AS, Willis MS, Selzman CH. Protea-some inhibition promotes regression of left ventricular hypertrophy. Am J Physiol Heart Circ Physiol 2008;294:H645-H650.
75. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 2002;105: 85-92.
76. Depre C, Hase M, Gaussin V, Zajac A, Wang L, Hittinger L et al. H11 kinase is a novel mediator of myocardial hypertrophy in vivo. Circ Res 2002;91: 1007-1014.
77. Depre C, Wang L, Sui X, Qiu H, Hong C, Hedhli N et al. H11 kinase prevents myocardial infarction by preemptive preconditioning of the heart. Circ Res 2006; 98:280-288.
78. Sui X, Li D, Qiu H, Gaussin V, Depre C. Activation of the bone morphogenetic protein receptor by H11Kinase/Hsp22 promotes cardiac cell growth and survival. Circ Res 2009;104:887-895.
79. Gallagher GL, Jackson CJ, Hunyor SN. Myocardial extracellular matrix remodeling in ischemic heart failure. Front Biosci 2007;12:1410-1419.
80. Weber K, Brilla C. Pathological hypertrophy and cardiac interstitium. Circulation 1991;83:1849-1865.
81. Iimoto D, Covell J, Harper E. Increase in cross-linking of type 1 and type 3 col-lagens associated with volume overload hypertrophy. Circ Res 1988;63:399-408.
82. Gonzalez A, Lopez B, Querejeta R, Diez J. Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease? J Mol Cell Cardiol 2002;34:1585-1593.
83. Funck RC, Wilke A, Rupp H, Brilla CG. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv Exp Med Biol 1997;432: 35-44.
84. Hayden MS, Ghosh S. Signaling to NF-kB. Genes Dev 2004;18:2195-2224.
85. Gao Y, Lecker S, Post MJ, Hietaranta AJ, Li J, Volk R et al. Inhibition of ubiquitin-proteasome pathway-mediated IkB a degradation by a naturally occurring antibacterial peptide. J Clin Invest 2000;106:439-448.
86. Gaczynska M, Osmulski PA, Gao Y, Post MJ, Simons M. Proline-and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity. Biochemistry 2003;42:8663-8670.
87. Li J, Post M, Volk R, Gao Y, Li M, Metais C et al. PR39, a peptide regulator of angiogenesis. Nat Med 2000;6:49-55.
88. Post MJ, Sato K, Murakami M, Bao J, Tirziu D, Pearlman JD et al. Adenoviral PR39 improves blood flow and myocardial function in a pig model of chronic myocar-dial ischemia by enhancing collateral formation. Am J Physiol Regul Integr Comp Physiol 2006;290:R494-R500.
89. Weber K. Extracellular matrix remodeling in heart failure. Circulation 1997;96: 4065-4082.
90. Foody J, Farrell M, Krumholz H. b-Blocker therapy in heart failure. JAMA 2002; 287:883-889.
91. Sanders PM, Russell ST, Tisdale MJ. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br J Cancer 2005;93:425-434.
92. Russell ST, Eley HL, Tisdale M. Mechanism of attenuation of angiotensin-II-induced protein degradation by insulin-like growth factor-I (IGF-I). Cell Signal 2007;19: 1583-1595.
93. Song Y-H, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 2005;115:451-458.
94. Asai M, Tsukamoto O, Minamino T, Asanuma H, Fujita M, Asano Y et al. PKA rapidly enhances proteasome assembly and activity in in vivo canine hearts. J Mol Cell Cardiol 2009;46:452-462.
95. Hayashidani S, Tsutsui H, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 2003;285: H1229-H1235.
96. van den Borne S, Cleutjens J, Hanemaaijer R, Creemers E, Smits J, Daemen M et al. Increased matrix metalloproteinase-8 and-9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol 2008;Feb 21
97. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest 2005;115:599-609.
98. Gao X, Dilley R, Samuel C, Percy E, Fullerton M, Dart A et al. Lower risk of post-infarct rupture in mouse heart overexpressing b2-adrenergic receptors: importance of collagen content. J Cardiovasc Pharmacol 2002;40:632-640.